Citations

Institution: Mayo Clinic Clear

Showing 10 of 108119 citations.

Exercise Mildly Increases Transaortic Gradients in Aortic Stenosis With Preserved Ejection Fraction: An Invasive Hemodynamic Study
Al‐Abcha, Abdullah , Jain, C. Charles , Nishimura, Rick A., Simard, Trevor , Eleid, Mackram F. , Hibbert, Benjamin , Oh, Jae K., Carabello, Blasé A. , Miranda, William R. , Simard, Trevor , Hibbert, Benjamin , Al-Abcha, Abdulah , Oh, Jae K.

Catheterization and Cardiovascular Interventions | April 9, 2025 | Volume: 106 | Issue: 1 | Pages: 181-188

10.1002/ccd.31511 | PMID 40202054 Get It

ABSTRACT Background The assessment of aortic stenosis (AS) severity remains a challenge in some patients, and hemodynamic exercise testing has been proposed as a diagnostic tool in this population. However, the current understanding of exercise hemodynamics in AS is limited. Methods Retrospective review of 34 adults (aged ≥ 18 years) with ≥ moderate AS and preserved left ventricular ejection fraction (LVEF) undergoing exercise invasive hemodynamics (supine cycle protocol) with simultaneous measurement of aortic and left ventricular pressures. Results Age was 77.1 (IQR 68.6; 84.1) years, and 50% were female. LVEF was 62.1 ± 6.6%. All patients were symptomatic. Resting aortic valve area (AVA) was 1.0 ± 0.2 cm 2 and aortic valve (AV) systolic mean gradient 22.0 ± 7.3 mmHg. At peak exercise (40 [IQR 30; 60] W), AV systolic mean gradient (Δ3 [0.6; 7] mmHg, p < 0.001) and AVA (Δ0.2 [0; 0.6] cm 2 , p = 0.002) significantly increased, while stroke volume (SV) did not (Δ6.8 ± 19.4 ml; p = 0.07). Exercise‐induced changes in AV systolic mean gradient were directly related to changes in cardiac output ( r = 0.53, p = 0.003), being inversely related to exercise systemic vascular resistance ( r = −0.60, p = 0.002). Elevated pulmonary artery wedge pressure was present in 41.2% at rest (≥ 15 mmHg) and 69.7% during exercise (≥ 25 mmHg). Conclusions Symptomatic patients with ≥ moderate AS and preserved LVEF experience small increases in AV mean gradient with exercise, and unlike the normal physiological response to exercise, there was no significant increase in SV. In most patients, AVA rose during exercise. Exercise‐induced elevation in filling pressures was highly prevalent.
Medical Therapy Versus Percutaneous Coronary Intervention in Patients with Myocardial Bridging from a National Population-Based Cohort Study: The Use of Big Data Analytics
Krittanawong, Chayakrit , Padilla, Ferran , Qadeer, Yusuf Kamran , Wang, Zhen , Sharma, Samin K. , Lavie, Carl J., Schaff, Hartzell V. , Schwarz, Ernst R. , Sharma, Samin K , Schaff, Hartzell , Ang, Song Peng , Gaibazzi, Nicola , Lavie, Carl J.

Cardiogenetics | April 9, 2025 | Volume: 15 | Issue: 2 | Pages: 10

10.3390/cardiogenetics15020010 Get It

Myocardial Bridging (MB) is typically a benign congenital coronary anomaly. MB can infrequently result in complications such as myocardial ischemia, arrhythmias, and sudden cardiac death. Recent studies suggest an underlying genetic component for MB involving DES, FBN1, SCN2B, or NOTCH1. The role of percutaneous coronary intervention (PCI) in managing MB, compared to optimal medical therapy (OMT), remains uncertain. Our study used the National Inpatient Sample (NIS) Database to identify patients aged 18 or older with myocardial bridging who were managed with PCI versus medical therapy. We compared the outcomes between both groups including in-hospital mortality, the trend of management of MB and other in-hospital outcomes or complications. Our results showed no statistically significant difference between both subgroups when comparing in-hospital mortality and secondary outcomes of cardiac arrest and the development of an acute kidney injury (AKI). Patients with myocardial bridging treated with PCI had a higher risk of developing cardiogenic shock, requiring LVAD, and requiring the use of intra-aortic balloon pump (IABP) compared to the medical therapy subgroup. Our study suggests the decision to perform PCI in myocardial bridging patients should be individualized such as in patients with refractory symptoms despite medical therapy or those with known high-risk features.
Use of an Intraoperative Head, Neck, and Back Support Exoskeleton on Surgeons’ Pain and Posture
Kim, Joseph , Cassivi, Stephen D. , Black, Dalliah M. , Kim, Joseph Y , Norasi, Hamid , Hallbeck, M Susan , Hallbeck, M. Susan

Annals of Surgery | April 9, 2025 | Volume: 283 | Issue: 2 | Pages: 184-191

10.1097/sla.0000000000006723 | PMID 40201977 Get It

Objective: To evaluate the effectiveness of an intraoperative exoskeleton that supports surgeons’ heads, necks, and backs to reduce neck discomfort. Background: Surgeons are at a considerable risk of developing neck pain and related injuries. Passive exoskeletons are a potential intervention to support surgeons’ body parts and alleviate strain and discomfort. Methods: The NekSpine (a passive neck exoskeleton) was trialed on 12 surgeons (7 males and 5 females) across 6 specialties. Each surgeon performed 4 surgical procedures, 2 with the NekSpine (exoskeleton) and 2 without (baseline). Exoskeleton and baseline surgeries were paired primarily by surgical procedure and secondarily by duration. Surgeons completed surveys that included the NASA-TLX and usability questions before and after surgical procedures to evaluate body part discomfort, overall fatigue, workload, and potential disruptions to the surgical workflow. Surgeons also wore inertial measurement units to objectively record their upper arms, neck, and torso postures. Results: Use of the exoskeleton yielded significant decreases in discomfort in the neck, left shoulder, right shoulder, and left arm. Reductions in percent surgical duration in risk 4 (extreme risk postures) coupled with increases spent in risk 2 (moderate risk postures) for the neck and torso were noted. Surgeons reported overall favorable usability results with the exoskeleton not interfering with the surgical workflow, and most stated that they would use the exoskeleton again. Conclusions: The NekSpine is a promising intervention to alleviate surgeons’ neck discomfort and improve their neck and torso postures.
Precision Prevention through Social Media: Report of Four Cases
López–Campos, Guillermo , Davies, Shauna , Petersen, Carolyn , Petersen, Carolyn , Gabarrón, Elia , Chomutare, Taridzo , Isip-Tan, Iris Thiele

Yearbook of Medical Informatics | April 8, 2025 | Volume: 33 | Issue: 01 | Pages: 052-057

10.1055/s-0044-1800718 | PMID 40199288 Get It

Summary Background: Precision prevention involves using biological, behavioral, socioeconomic, and epidemiological data to improve health for a particular individual or group. With almost 63% of the global population using social media, these platforms show promise to deliver tailored messaging and personalized interventions to individuals. Objectives: To describe the personalization elements and behavior components used in a sample of precision prevention interventions delivered through social media. Methods: To identify examples of cases, a search was done on clinicaltrials.gov, searching for ‘other terms: prevention’ + ‘Intervention/Treatment: social media intervention’ + ‘study results: With results. The selected cases were described, personalization elements reported, and their adopted intervention components were coded according to the Behavior Change Wheel (BCW) framework. Results: A total of four cases employing personalization in their interventions were identified. Three of these cases targeted women's health. The intervention period varied from two to eight months, with participant commitment ranging from active involvement on five out of seven days to monthly participation. The BCW interventions of persuasion and incentivization, were most frequently utilized, while education and coercion were used sparingly in the selected cases. Notably, none of the four cases reported the use of training, restrictions, or modeling. Conclusions: Social media has the potential to serve as a tool for digital phenotyping and contribute to the advancement of precision prevention. Challenges include the social media platform set-up and ensuring all ethical considerations are met.
Cellular and molecular mechanisms underlying aging-related gastric neuromuscular dysfunction
Zhang, Yuebo , Choi, Egan L. , Hayashi, Yujiro

Journal of Smooth Muscle Research | April 8, 2025 | Volume: 61 | Pages: 43-50

10.1540/jsmr.61.43 | PMID 40204454 Get It

Consensus disease definitions for ophthalmic immune-related adverse events of immune checkpoint inhibitors
Chang, Eileen , Keyhanian, Kiandokht, Huynh, Katie , Bhatti, M. Tariq , Chen, John J. , Costello, Fiona , Lott, Lindsey B. De , Egan, Robert A. , Fraser, Clare L, Freitag, Suzanne K. , Guidon, Amanda C. , Johnson, Douglas B. , Kombo, Ninani , Kramer, Michal , Lobo-Chan, Anne-Marie, Mantopoulos, Dimosthenis , Papaliodis, George N. , Pimkina, Julia, Rubin, Krista M., Sen, H. Nida, Shariff, Afreen , Subramanian, Prem S. , Tsui, Edmund , Yoon, Michael K. , McDunn, Jon, Rine, Johnathan, Reynolds, Kerry L. , Chwalisz, Bart K. , Levy, Michael , Huynh, Katie , Pless, Misha, Levy, Michael , Chen, John J , De Lott, Lindsey B , Liu, Renee , Berkenstock, Meghan , Chodosh, James , Dalvin, Lauren A. , Dinkin, Marc , Fraser, Clare L, Gangaputra, Sapna , Gordon, Lynn K. , Lee, Andrew G. , Levy, Michael, Lobo-Chan, Ann-Marie , Pless, Misha L , Sen, H. Nida , McDunn, Jon , Sobrin, Lucia

Journal for ImmunoTherapy of Cancer | April 8, 2025 | Volume: 13 | Issue: 4 | Pages: e011049

10.1136/jitc-2024-011049 | PMID 40199607 Get It

Ophthalmic immune-related adverse events (Eye-irAEs) from immune checkpoint inhibitors can cause visual morbidity. The absence of standardized definitions for Eye-irAEs not only impedes the development of evidence-based treatments but also progress in translational research. The objective of this study was to develop consensus guidance for an approach to Eye-irAEs. Four ophthalmic physicians (uveitis specialists and neuro-ophthalmologists) drafted Eye-irAE consensus guidance and definitions, which were reviewed by the multidisciplinary Eye-irAE definition panel. The panel was divided into Group A (Neuro-ophthalmology/Orbital Disease) and Group B (Uveitis/Ocular Surface Disease). A modified Delphi consensus process was used, with two rounds of anonymous ratings by panelists and two meetings to discuss areas of controversy. For each disorder, five diagnostic components were evaluated: symptoms, examination findings, laboratory studies/imaging findings, diagnostic criteria, and treatment. Panelists rated content for usability, appropriateness and accuracy on 9-point scales in electronic surveys and provided free-text comments. Aggregated survey responses were incorporated into revised definitions. Consensus was based on numeric ratings using the RAND Corporation/ University of California Los Angeles Health Services Utilization Study (RAND/UCLA) Appropriateness Method with prespecified definitions. 29 panelists from 25 academic medical centers voted on 114 rating scales (66 neuro-ophthalmic/orbital disease components, 48 uveitis/ocular surface disease components); of these, 86.3% (57/66) in Group A and 89.6% (43/48) in Group B reached first-round consensus. After revisions, all items except 6.1% (4/66) in Group A and 1.6% (1/60) in Group B received second-round consensus. Consensus definitions were achieved for 10/11 neuro-ophthalmic/orbital disorders: optic neuritis, inflammatory optic disc edema, arteritic ischemic optic neuropathy, optic perineuritis, orbital inflammation, thyroid eye disease-like orbital inflammation, cavernous sinus syndrome, oculomotor mononeuritis, trochlear mononeuritis, and abducens mononeuritis. Consensus definitions were achieved for 9/10 uveitis/ocular surface disorders: anterior uveitis, intermediate uveitis, posterior uveitis, panuveitis, Vogt-Koyanagi-Harada-like syndrome, sarcoidosis-like syndrome, acute macular neuroretinopathy, dry eye disease, and scleritis. These disease definitions establish a standardized classification for Eye-irAE, highlighting differences between irAEs and other inflammatory disorders. Importantly, diagnostic certainty does not always align directly with the need to treat as an Eye-irAE. Given the consensus from this representative panel group, it is anticipated the definitions will be used broadly across clinical and research settings.
Gastrostomy Tubes in Trauma Patients
Chan, Johanna , Huang, Steven Y. , Lin, Yuan‐Mao , Murthy, Ravi

Digestive Disease Interventions | April 8, 2025 | Volume: 10 | Issue: 02 | Pages: 102-107

10.1055/s-0045-1807246 Get It

Abstract Gastrostomy tubes provide essential long-term enteral nutritional support for trauma patients unable to tolerate oral intake or if prohibited due to associated injuries. This review aims to explore the indications and special considerations unique to gastrostomy tube placement and management for patients following trauma. The specific special considerations addressed in this article are timing of gastrostomy tube placement, timing of gastric tube feeding, technique, indications for postpyloric feeding tubes, concomitant corticosteroid use, safety in patients with an open abdomen, overcoming an inability to pass a nasogastric tube, and considerations for postgastrostomy tube management.
Letter to the FDA Proposing Major Changes in the US Clozapine Package Insert Supported by Clozapine Experts Worldwide. Part I
León, José de , Baldessarini, Ross J. , Balon, Richard , Bilbily, John , Citrome, Leslie , Cotes, Robert O. , Davis, John M. , DeLisi, Lynn E. , Faden, Justin , Freudenreich, Oliver , Goldsmith, David R. , Gurrera, Ronald J. , Josiassen, Richard C. , Kelly, Deanna L. , Laitman, Robert S., Lam, Y. W. Francis , Love, Raymond C. , McCollum, Betsy , Meyer, Jonathan M. , Nasrallah, Henry A. , Nucifora, Frederick C. , Rothschild, Anthony J. , Shelton, Charles , Sher, Leo , Zarzar, Theodore R. , Sanz, Emílio J. , Cuevas, Carlos De las , de Leon, Jose , Caroff, Stanley N , Citrome, Leslie , Correll, Christoph Ulrich , Cotes, Robert O , Davis, John M , Faden, Justin , Freudenreich, Oliver , Gurrera, Ronald , Kane, John M , Laitman, Robert S , Lam, Y W Francis , Leung, Jonathan G , Love, Raymond C , McCollum, Betsy , McGrane, Ian , Meyer, Jonathan M , Nasrallah, Henry A , Rothschild, Anthony J , Rubio, Jose M , Sarpal, Deepak K , Schoretsanitis, Georgios , Shad, Mujeeb , Shelton, Charles , Sher, Leo , Singh, Balwinder , Surya, Sandarsh , Zarzar, Theodore R , Sanz, Emilio J , De Las Cuevas, Carlos , Kane, John M. , Keshavan, Matcheri S. , Leung, Jonathan G. , McGrane, Ian R. , Sajatovic, Martha , Schoretsanitis, Georgios , Singh, Balwinder

Journal of Clinical Psychopharmacology | April 8, 2025 | Volume: 45 | Issue: 3 | Pages: 179-196

10.1097/jcp.0000000000001987 | PMID 40198781 Get It

Abstract Purpose/Background Clozapine was approved in the United States (US) using 1989 regulations and knowledge. After 30 years, many sections of the US package insert (PI) are outdated. Methods We comprehensively reviewed the literature to propose PI updates. We present the information in 2 articles. In Part I, we focus on basic pharmacology based on 407 relevant articles. Part II focuses on clinical aspects and pharmacovigilance. Findings/Results Based on more recent expectations of Food and Drug Administration regulations, we reviewed clozapine basic pharmacology including the following: 1) clearance, 2) pharmacokinetics and pharmacodynamics, and 3) monitoring tools. We identified 9 major problems in the basic pharmacological sections of the PI including the following: 1) in vivo studies indicate that clozapine is dependent on CYP1A2 for its metabolism, 2) the minor role of CYP2D6 in clozapine metabolism requires removing the PI recommendation to lower clozapine doses in CYP2D6 poor metabolizers, 3) in nontoxic concentrations CYP3A4 has a minor role in clozapine metabolism and potent CYP3A4 inhibitors lack clinically relevant effects, 4) several drug-drug interactions need to be updated based on recent literature, 5) systemic inflammation may decrease clozapine metabolism and increase the risk of clozapine intoxication, 6) obesity may decrease clozapine metabolism, 7) patients of Asian and Indigenous American ancestry need lower clozapine doses, 8) personalized titration and c-reactive protein monitoring should be considered until prospective studies are available, and 9) the half-life section needs to be modified to acknowledge that single dosing at night is frequent in the US. Implications/Conclusions An improvement in the US clozapine PI may lead to improvement in PIs worldwide.
Convergent Genetic Adaptation in Human Tumors Developed Under Systemic Hypoxia and in Populations Living at High Altitudes
Arenillas, Carlota , Celada, Lucía , Ruiz-Cantador, José , Calsina, Bruna , Datta, Debayan , García‐Galea, Eduardo , Fasani, Roberta , Moreno-Cárdenas, Ana Belén , Alba‐Linares, Juan José , Miranda, Berta , Martínez‐Montes, Ángel M. , Álvarez-Escolá, Cristina , Lecumberri, Beatriz , García, Ana González , Flores, Shahida K., Esquivel, Emmanuel , Ding, Yanli , Peitzsch, Mirko , Robles-Guirado, José-Ángel , Zapata, Rita Maria Regojo , Iglesias, Carmela , Dwight, Trisha , Oleaga, Amelia , Garrido‐Lestache, Elvira , Marín, María Jesús del Cerro , Martínez-Bendayán, Isaac , Álvarez-González, Enol , Cubiella, Tamara, Lourenço, Delmar Muniz , Pereira, Maria Adelaide Albergaria, Burnichon, Nelly , Broberg, Craig S. , Dickson, Paxton V. , Soriano, Joaquín Rueda , Dienstmann, Rodrigo , Villanueva, Josep , Capdevila, Jaume , Gimenez‐Roqueplo, Anne‐Paule , Bechmann, Nicole , Vaidya, Anand , Weghorn, Donate , Casteràs, Anna , Adameyko, Igor , Miranda-Barrio, Berta , González García, Ana , K Flores, Shahida , Regojo Zapata, Rita Maria , Pozo-Kreilinger, José Juan , Iglesias, Carmela , Dwight, Trisha , Muir, Christopher A , Oleaga, Amelia , Garrido-Lestache Rodríguez-Monte, Maria Elvira , Del Cerro, Maria Jesús , Martínez-Bendayán, Isaac , Álvarez-González, Enol , Cubiella, Tamara , Lourenço, Delmar Muniz , A Pereira, Maria Adelaide , Burnichon, Nelly , Buffet, Alexandre , Broberg, Craig , Dickson, Paxton V , Fraga, Mario F , Llorente Pendás, José Luis , Rueda Soriano, Joaquín , Buendía Fuentes, Francisco , Toledo, Sergio P A , Clifton-Bligh, Roderick , Dienstmann, Rodrigo , Villanueva, Josep , Capdevila, Jaume , Gimenez-Roqueplo, Anne-Paule , Favier, Judith , Nuciforo, Paolo , Young, W F , Bechmann, Nicole , Opotowsky, Alexander R , Vaidya, Anand , Bancos, Irina , Weghorn, Donate , Robledo, Mercedes , Casteràs, Anna , Dos-Subirà, Laura , Adameyko, Igor , Chiara, María-Dolores , Dahia, Patricia L M , Toledo, Rodrigo A , Fraga, Mario F. , Nucíforo, Paolo , Young, William F. , Bancos, Irina , Chiara, María‐Dolores , Dahia, Patricia L. M.

Cancer Discovery | April 8, 2025 | Volume: 15 | Issue: 5 | Pages: 1037-1062

10.1158/2159-8290.cd-24-0943 | PMID 40199338 Get It

Abstract This study explores parallels between systemic hypoxia adaptation in high-altitude populations and tumorigenesis. We identified EPAS1, a gene critical for hypoxia adaptation in populations such as Tibetans and Sherpas, as playing a similar adaptive role in tumors arising under hypoxic conditions. Tumors from patients with chronic hypoxia displayed impaired DNA repair and frequent emergence of EPAS1 variants, with frequencies reaching up to 90%, echoing the positive selection seen in high-altitude dwellers. Mechanistically, EPAS1 gain-of-function mutations promote COX4I2 expression, reducing cellular oxygen consumption and supporting tumor proliferation in hypoxia. Analysis of clinical data from patients with hypoxia revealed tissue-specific and time-sensitive tumorigenic effects, particularly impacting oxygen-sensitive cells in the postnatal period. Our findings suggest that EPAS1-driven adaptation mechanisms in high-altitude populations provide a model for understanding tumor evolution under hypoxic stress, highlighting how genetic adaptations to diverse stressors in natural populations may yield insights into tumorigenesis and cancer progression. Significance: This study reveals a broad convergence in genetic adaptation to hypoxia between natural populations and tumors, suggesting that insights from natural populations could enhance our understanding of cancer biology and identify novel therapeutic targets. See related commentary by Lee, p. 875
Letter to the FDA Proposing Major Changes in the US Clozapine Package Insert Supported by Clozapine Experts Worldwide. Part II
León, José de , Baldessarini, Ross J. , Balon, Richard , Bilbily, John , Citrome, Leslie , Cotes, Robert O. , Davis, John M. , DeLisi, Lynn E. , Faden, Justin , Freudenreich, Oliver , Goldsmith, David R. , Gurrera, Ronald J. , Josiassen, Richard C. , Kelly, Deanna L. , Laitman, Robert S., Lam, Y. W. Francis , Love, Raymond C. , McCollum, Betsy , Meyer, Jonathan M. , Nasrallah, Henry A. , Nucifora, Frederick C. , Rothschild, Anthony J. , Shelton, Charles , Sher, Leo , Zarzar, Theodore R. , Sanz, Emílio J. , Cuevas, Carlos De las , de Leon, Jose , Caroff, Stanley N , Citrome, Leslie , Correll, Christoph Ulrich , Cotes, Robert O , Davis, John M , Faden, Justin , Freudenreich, Oliver , Gurrera, Ronald , Kane, John M , Laitman, Robert S , Lam, Y W Francis , Leung, Jonathan G , Love, Raymond C , McCollum, Betsy , McGrane, Ian , Meyer, Jonathan M , Nasrallah, Henry A , Rothschild, Anthony J , Rubio, Jose M , Sarpal, Deepak K , Schoretsanitis, Georgios , Shad, Mujeeb , Shelton, Charles , Sher, Leo , Singh, Balwinder , Surya, Sandarsh , Zarzar, Theodore R , Sanz, Emilio J , De Las Cuevas, Carlos , Kane, John M. , Keshavan, Matcheri S. , Leung, Jonathan G. , McGrane, Ian R. , Sajatovic, Martha , Schoretsanitis, Georgios , Singh, Balwinder

Journal of Clinical Psychopharmacology | April 8, 2025 | Volume: 45 | Issue: 3 | Pages: 197-218

10.1097/jcp.0000000000001990 | PMID 40198784 Get It

Abstract Purpose/Background This is the second part of a 2-part article that proposes improving the United States (US) clozapine package insert. Part II focuses on fatal outcomes and the 5 boxed warnings, 4 specifically for clozapine: severe neutropenia, seizure, orthostatic hypotension and myocarditis, and 1 for all antipsychotics (elderly with dementia). Methods US reports to the World Health Organization's global pharmacovigilance database were analyzed from clozapine's introduction to January 15, 2023. Findings/Results The US was the top reporter worldwide for clozapine with 56,003 reports and 9587 associated fatal outcomes. The 4 clozapine boxed warnings were associated with 534 fatal outcomes (218 with severe neutropenia, 131 with seizures, 125 with orthostasis, 36 with myocarditis, 24 with cardiomyopathy, and 0 with mitral valve prolapse). With no boxed warnings, pneumonia was associated with 674 fatal outcomes and increased white blood cell count (a sign of infection) with 596 fatal outcomes. After considering overlaps, pneumonia and increases in white blood cell count explained 900 fatalities, or 9.4% of 9587 fatal outcomes. The Food and Drug Administration continues to focus on severe neutropenia which was associated with only 218 or 2.3% of fatal outcomes, whereas 97.7% of fatal outcomes reported in US clozapine-treated patients had another cause. Implications/Conclusions To help prevent future deaths in clozapine-treated patients, the clozapine package insert should focus on fatal outcomes during infections. Part II offers detailed solutions regarding current boxed warnings and lack of a warning for pneumonia and other infections. The Supplementary Material includes letters of support from 124 non-US clozapine experts from 44 countries/regions who support Parts I and II.